Myelofibrosis Excellence Forum

Myelofibrosis

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Q&As

Evaluating the Correlation Between Anemia and Blast Phase Evolution Risk Among Patients With Myelofibrosis

02/21/2024

Featuring Francesca Palandri, MD, PhD

Featuring Francesca Palandri, MD, PhD...

Francesca Palandri, MD, PhD, evaluates the correlation between anemia and an increased risk of evolution into blast phase for patients with ruxolitinib-treated myelofibrosis.

Francesca Palandri, MD, PhD,...

02/21/2024

Oncology

Videos

Mitigating Potential Treatment Risks Among Patients With Myelofibrosis

02/02/2024

Featuring Aaron Gerds, MD

Aaron Gerds, MD, examines potential treatment risks for patients with myelofibrosis and how to mitigate them in order to achieve the best possible outcomes.

Aaron Gerds, MD, examines...

02/02/2024

Oncology

Videos

Exploring the Benefits of Momelotinib for Patients With Myelofibrosis, Including With Anemia

02/02/2024

Featuring Aaron Gerds, MD

Aaron Gerds, MD, discusses the phase 3 MOMENTUM trial on momelotinib treatment for patients with myelofibrosis, including those with anemia, which served as the basis for the approval of momelotinib by the US FDA.

Aaron Gerds, MD, discusses the...

02/02/2024

Oncology

Conference Coverage

Examining Predictors of Emergent Thrombocytopenia After Ruxolitinib Treatment Among Patients With Myelofibrosis

01/03/2024

Featuring Douglas Tremblay, MD

Featuring Douglas Tremblay, MD ...

At the 2023 ASH Annual Meeting, Douglas Tremblay, MD, discussed the prevalence and predictors of emergent thrombocytopenia following ruxolitinib treatment among patients with myelofibrosis.

At the 2023 ASH Annual Meeting,...

01/03/2024

Oncology

Claire Harrison, MD, FRCP, Guy’s and St. Thomas’ NHS Foundation Trust

Conference Coverage

Ruxolitinib Therapy Demonstrates Reduced JAK2 Allele Burden and Improvement in Hematocrit Control and Symptom Burden for Patients With PV

12/21/2023

Featuring Claire Harrison, MD, FRCP

Featuring Claire Harrison, MD, FRCP ...

At the 65th ASH Annual Meeting in San Diego, California, Claire Harrison, MD, FRCP discussed a pooled efficacy analysis that provided further evidence of the benefit of ruxolitinib treatment for patients with polycythemia vera, with or...

At the 65th ASH Annual Meeting...

12/21/2023

Oncology

Pankit Vachhani, MD, O’Neal Comprehensive Cancer Center

Conference Coverage

Platelet Count Response Among Patients With Cytopenic Myelofibrosis Treated With Pacritinib

12/21/2023

Featuring Pankit Vachhani, MD

At the 65th ASH Annual Meeting in San Diego, California, Pankit Vachhani, MD, presented data that platelet count improvement occurred in a subset of patients with myelofibrosis treated with pacritinib.

At the 65th ASH Annual Meeting...

12/21/2023

Oncology

Ruben A. Mesa, MD, FACP, Atrium Health Wake Forest Baptist Comprehensive Cancer Center

Videos

Novel Advances in the Treatment of Patients With Myelofibrosis

11/07/2023

Featuring Ruben A. Mesa, MD, FACP

Featuring Ruben A. Mesa, MD, FACP ...

At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Ruben A. Mesa, MD, FACP, discusses the latest updates in myelofibrosis treatment.

At the 2023 Lymphoma, Leukemia &...

11/07/2023

Lymphoma, Leukemia & Myeloma Network

Videos

Recent Advancements in Clinical Development for the Treatment of Myelofibrosis

05/04/2023

At the 2023 Great Debates & Updates in Hematologic Malignancies conference, New York, John Mascarenhas, MD, discussed recent advancements in clinical developments for the treatment of myeloproliferative neoplasms, specifically myelofibrosis,...

At the 2023 Great Debates &...

05/04/2023

Oncology

Videos

Momelotinib Demonstrates Consistent Long-Term Safety in Patients With Myelofibrosis

01/19/2023

Srdan Verstovsek, MD, discusses the long-term safety of momelotinib in patients with high- and intermediate-risk myelofibrosis, using data from 3 randomized controlled trials: SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM.

Srdan Verstovsek, MD, discusses...

01/19/2023

Oncology

Videos

Ruxolitinib in Patients With Myelofibrosis Who Had Anemia or Thrombocytopenia: Real-World Outcomes

12/20/2022

Srdan Verstovsek, MD, presents data on real-world outcomes of the use of ruxolitinib in patients with myelofibrosis who had anemia or thrombocytopenia at the ASH 2022 Meeting in New Orleans, LA.

Srdan Verstovsek, MD, presents...

12/20/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology